Gastroesophageal adenocarcinoma (GEA) is a lethal disease where targeted therapies,
even when guided by genomic biomarkers, have had limited efficacy. A potential reason for …

Barrett's esophagus is thought to progress to esophageal adenocarcinoma (EAC) through a
stepwise progression with loss of CDKN2A followed by TP53 inactivation and aneuploidy …

Leiomyosarcoma (LMS) is an aggressive mesenchymal malignancy with few therapeutic
options. The mechanisms underlying LMS development, including clinically actionable …

Burkitt lymphoma is a mature aggressive B-cell lymphoma derived from germinal center B
cells. Its cytogenetic hallmark is the Burkitt translocation t (8; 14)(q24; q32) and its variants …

Glioblastoma (GBM) is a prototypical heterogeneous brain tumor refractory to conventional
therapy. A small residual population of cells escapes surgery and chemoradiation, resulting …

Esophageal squamous cell carcinoma (ESCC) develops through a series of increasingly
abnormal precancerous lesions. Previous studies have revealed the striking differences …

Whole Exome Sequencing (WES) is the application of the next‐generation technology to
determine the variations in the exome and is becoming a standard approach in studying …

Cancer drug screening in patient‐derived cells holds great promise for personalized
oncology and drug discovery but lacks standardization. Whether cells are cultured as …

Incomplete understanding of the metastatic process hinders personalized therapy. Here we
report the most comprehensive whole-genome study of colorectal metastases vs. matched …

The need for new safe and efficacious therapies has led to an increased focus on biologics
produced in mammalian cells. The human cell line HEK293 has bio-synthetic potential for …